De-Risking Drug Discovery with ADDME - Avoiding Drug Development Mistakes Early

被引:12
|
作者
Tsaioun, Katya [1 ]
Jacewicz, Mary [1 ]
机构
[1] Apredica, Watertown, MA USA
关键词
ADME; ADMET; DMPK; drugability; drug discovery; pharmacokinetic studies; PK; toxicity; toxicology; TOXICITY; CELLS; HEPATOTOXICITY; PERMEABILITY; CONCORDANCE; TERFENADINE; SOLUBILITY; INNOVATION; CULTURE;
D O I
10.1177/026119290903701S10
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The advent of early Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) screening has increased the elimination rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and why it has become so important in drug discovery and development. Assays that have been developed in response to specific needs, and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of toxicity, are discussed; The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 50 条
  • [1] ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
    Katya Tsaioun
    Michel Bottlaender
    Aloise Mabondzo
    [J]. BMC Neurology, 9
  • [2] ADDME - Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
    Tsaioun, Katya
    Bottlaender, Michel
    Mabondzo, Aloise
    [J]. BMC NEUROLOGY, 2009, 9
  • [3] Development of a neuronal scoring systemin vitro for potential hazard identification in early drug safety de-risking
    Kreir, Mohamed
    Putri, Dea
    Tekle, Fetene
    Van Ammel, Karel
    Lu, Hua Rong
    Teisman, Ard
    Gallacher, David J.
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2023, 123
  • [4] De-Risking Clinical Development
    Greene, Douglas A.
    [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (03): : 38 - 39
  • [5] Target safety assessments and their role in de-risking drug discovery: NaV1.7 as an example
    Eades, Lauren
    Sadler, Claire
    Knight, Richard
    Morton, Michael
    Roberts, Ruth
    [J]. TOXICOLOGY LETTERS, 2017, 280 : S224 - S225
  • [6] De-risking the discovery and development of new drugs from bench to clinic
    Ilyin, SE
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (11) : 1031 - 1031
  • [7] Developability assessment as an early de-risking tool for biopharmaceutical development
    Zurdo, Jesus
    [J]. PHARMACEUTICAL BIOPROCESSING, 2013, 1 (01) : 29 - 50
  • [8] De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits
    Ng, Simon
    Juang, Yu-Chi
    Chandramohan, Arun
    Kaan, Hung Yi Kristal
    Sadruddin, Ahmad
    Yuen, Tsz Ying
    Ferrer-Gago, Fernando J.
    Lee, Xue'Er Cheryl
    Liew, Xi
    Johannes, Charles W.
    Brown, Christopher J.
    Kannan, Srinivasaraghavan
    Aronica, Pietro G.
    Berglund, Nils A.
    Verma, Chandra S.
    Liu, Lijuan
    Stoeck, Alexander
    Sawyer, Tomi K.
    Partridge, Anthony W.
    Lane, David P.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (10): : 1993 - 2001
  • [9] Development of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification in Early Drug Safety De-risking
    Kopljar, Ivan
    Lu, Hua Rong
    Van Ammel, Karel
    Otava, Martin
    Tekle, Fetene
    Teisman, Ard
    Gallacher, David J.
    [J]. STEM CELL REPORTS, 2018, 11 (06): : 1365 - 1377
  • [10] Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
    Etkin, Amit
    Powell, Jessica
    Savitz, Adam J.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2024,